Tirzepatide is the first dual-target therapy that activates both GIP and GLP-1 receptors, helping manage blood sugar levels ...

Eli Lilly's (LLY) sees a 60% sales jump from April to May in India for its obesity/ diabetes drug Mounjaro. Read more here.

CompanyOverview|NYSE:NVO] Despite a massively successful run as Chief Executive Officer (CEO) of pharma giant Novo Nordisk ...

The manufacturer of Mounjaro has responded to dangerous hack that’s been doing the rounds on social media. Videos of people ...

This is the first time a regulator has confirmed the side effect. Read more at straitstimes.com. Read more at straitstimes.com.

A novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing ...

Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60% in India in May from April in its second full month of being on offer in the South Asian country, which has the world’s ...

With three months since its launch in India, according to latest Pharmatrac data, Mounjaro clocked Rs 12.6 crore in sales in May 2025—a threefold increase from March ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.